ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,304.72
      0.70%
      US Tech 100
      18,318.00
      0.95%
      Dow Jones
      39,069.59
      0.01%
      Brent Oil
      81.965
      0.00%
      Bitcoin
      69,279.92
      0.02%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

      7. Peregrine Pharmaceuticals Inc. (MM) (PPHMD) News

      PPHMD

      Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

      Peregrine Pharmaceuticals Inc. (MM)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PPHMD
      DateTimeSourceHeadlineSymbolCompany
      03/29/20196:42PMBusiness WireAnnouncing VanEck Vectors ETFs’ March 2019 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      12/26/20186:37PMBusiness WireAnnouncing VanEck Vectors Equity ETFs December 2018 DistributionNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      10/17/201811:48AMBusiness WireVanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports IndustryNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      09/28/20186:03PMBusiness WireAnnouncing VanEck Vectors Equity ETFs’ September 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      06/29/20186:15PMBusiness WireAnnouncing VanEck Vectors Equity ETFs June 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      03/29/20185:58PMBusiness WireAnnouncing VanEck Vectors Equity ETFs March 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      11/10/20099:30AMPR Newswire (US)New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain CancNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      11/04/20092:17PMPR Newswire (US)Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting AntibodiesNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      11/03/20093:00PMPR Newswire (US)Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing RequirementsNASDAQ:PPHMD
      10/27/20098:17AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      10/23/20095:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
      10/21/20099:30AMPR Newswire (US)Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerNASDAQ:PPHMD
      10/19/20099:30AMPR Newswire (US)Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory AffairsNASDAQ:PPHMD
      10/19/20098:30AMPR Newswire (US)Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes EffectNASDAQ:PPHMD
      10/19/20097:44AMEdgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
       Showing the most relevant articles for your search:NASDAQ:PPHMD